Key result
Intracoronary bone marrow stem cell therapy increases LVEF by ~6% vs control after AMI.
Why the study?
Small randomized controlled trials of intracoronary bone marrow stem cell therapy after acute myocardial infarction have yielded mixed results regarding improvement in cardiac function.
Does intracoronary bone marrow stem cell infusion improve left ventricular ejection fraction in patients after acute myocardial infarction?
Meta-Analysis (n=516)
Does intracoronary bone marrow stem cell infusion improve left ventricular ejection fraction in patients after acute myocardial infarction?
Mean Difference: 6.108 (95% CI 2.672–9.543)
p-value: p=<.001
Intracoronary bone marrow stem cell infusion significantly improves left ventricular systolic function at 3 to 6 months in patients following acute myocardial infarction.
Does not support routine intracoronary stem cell therapy after AMI; challenges animal data and leaves open optimized protocols for future trials.
BACKGROUND: Animal studies have suggested dramatic improvement in cardiac function after acute myocardial infarction (AMI) through regeneration of the myocardium or neovascularization by transfer of cells derived from bone marrow (BMC) generated clinical studies. Recently published small sized studies have yielded mixed results, leaving the question unanswered. HYPOTHESIS: We analyzed data from these studies in a meta-analysis to investigate if intracoronary stem cell therapy was effective in improving cardiac function. METHODS: A total of 7 randomized controlled trials meeting the inclusion criteria were identified by a systematic literature search. Primary endpoint was change in global left ventricular ejection fraction (LVEF) baseline to follow-up (ranging between 3 to 6 months). The meta-analysis consisted of 516 patients (BMC group, 256; control group, 260). A 2-sided alpha error of less than .05 was considered to be statistically significant (P<.05). RESULTS: There were no significant differences in patient characteristics between the BMC treatment and control groups at baseline. Compared to the control group, patients in the BMC treatment group had significantly greater increase in LVEF from baseline to follow-up (mean difference: 6.108%; SE: 1.753%; 95% confidence interval [CI]: 2.672%- 9.543%; P<.001). CONCLUSIONS: The present meta-analysis suggests that intracoronary bone marrow stem cell infusion may be effective in improving left ventricular systolic function in patients after acute myocardial infarction.
No takes yet. Share an insight, caveat, or question.
Singh et al. (2009) conducted a meta-analysis in Acute myocardial infarction (n=516). Intracoronary bone marrow stem cell therapy vs. Control was evaluated on Change in global left ventricular ejection fraction (LVEF) from baseline to follow-up (MD 6.108%, 95% CI 2.672%-9.543%, p=<.001). Intracoronary bone marrow stem cell therapy significantly increased left ventricular ejection fraction compared to control after acute myocardial infarction (MD 6.108%; 95% CI 2.672-9.543%; P<.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: